Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized treatment guided by automated fluid analysis in active neovascular age-related macular degeneration
2019-003133-42Phase 4Active
- Sponsor
- Medical University of Vienna
- Start
- Aug 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab, aflibercept and brolucizumab in exudative macular degeneration (2 cohorts), sponsored by Medical University of Vienna. Started Aug 2019; status: active.
02
Drugs
ranibizumabafliberceptbrolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-003133-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003133-42.